Synergistic effect of ethaselen and cisplatin treatment against tumor cell lines  

乙烷硒啉与顺铂联合应用对肿瘤细胞的协同效应分析(英文)

作　　者：李静[1] 傅佳凝[1] 谭强[1] 曾慧慧[1] 

机构地区：[1]北京大学天然药物及仿生药物国家重点实验室,北京100191

出　　处：《Journal of Chinese Pharmaceutical Sciences》2009年第4期337-341,共5页中国药学（英文版）

基　　金：National Natural Science Foundation of China (Grant No.30472036).

摘　　要：The antitumor activities of ethaselen （BBSKE） in combination with cisplatin （CDDP） in vitro have been investigated in human stomach cancer cell line BGC 823 and human lung cancer cell line PG-BE1. MTT method was used to assess the individual effects of ethaselen and cisplatin and their combined effects on cell proliferation of BGC 823 cells and PG-BE1 cells. Additionally, we used the classic median effect theory to calculate the combination index （CI） of ethaselen and cisplatin with different dose regimes in combination, and compared the effective dosages of cisplatin in individual treatment and combination treatment. When ethaselen and cisplatin were used in combination, a synergistic effect was observed. The most remarkable synergistic effect was observed when the dose ratio of cisplatin to ethaselen was 2：3 in BGC 823 cell line and 1：3 in PG-BE1 cell line. The dose of cisplatin could be decreased markedly in combination group to reach the same inhibitory effect, and this effect was gradually raised with the increase of the concentration of drugs.以人胃癌细胞BGC 823和人肺癌细胞PG-BE1为对象,研究乙烷硒啉与顺铂的体外联合抗肿瘤作用是否表现为协同增效。MTT法检测乙烷硒啉与顺铂单药及不同联合给药方案对BGC 823及PG-BE1细胞的增殖抑制作用;采用经典的中位效应理论计算不同联合方案时两药的联合指数CI,比较单药与联合时顺铂所需剂量的变化。结果显示,乙烷硒啉与顺铂联合可以产生协同作用。设置不同的给药剂量比例时,最明显的协同作用表现为:在人胃癌细胞BGC 823中,顺铂与乙烷硒啉比例为2:3;在人肺癌细胞PG-BE1中,顺铂与乙烷硒啉比例为1:3。乙烷硒啉与顺铂联合后,明显降低了顺铂的用量,并且随着药物浓度的升高,减量作用逐渐提高,起到了联合增效的作用。

关 键 词：Ethaselen （BBSKE） Cisplatin （CDDP） Synergistic effect 

分 类 号：R73-3[医药卫生—肿瘤]